Chlorinated lipid modification of proteins: Biomarkers of chlorine gas exposure
Chlorinated lipid modification of proteins: Biomarkers of chlorine gas exposure
批准号:
10160912
负责人:
DAVID A. FORD
金额:
$18.94万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2020
资助国家:
美国
项目状态:
已结题
起止时间:
2020-07-01 至 2023-06-30
关键词:
AccidentsAcidsAddressAlabamaAldehydesAmino Acid MotifsAmino AcidsAntibodiesBiological AssayBiological MarkersCaringChemical WarfareChemical Warfare AgentsChemicalsChemistryChlorineDependenceDetectionDiagnostic Reagent KitsDoseElectronsEmploymentEndothelial CellsEpithelial CellsExposure toFutureGasesGlutathioneHumanHypochlorous AcidInhalationInvestigationLeadLettersLipidsLungMaintenanceModificationMusOutcomeOxidantsPharmacologic SubstancePhospholipidsPlasmaPlasmalogensPost-Translational Protein ProcessingProductionProteinsPublic HealthResearch PersonnelStructureSwimming PoolsTherapeuticTissue BanksTrainingTransportationWateradductairway epitheliumanalogantibody detectionchlorine gascohortdetection assaydiagnostic biomarkerexposed human populationimprovedimproved outcomeinstrumentliquid chromatography mass spectrometrymanufacturing processnew therapeutic targetnoveloutcome predictionoxidationprotein biomarkersrapid detectionsignature moleculesynthetic peptidetherapeutic targetwater treatment
中文摘要
暴露于氯气(Cl2)对公众健康构成重大威胁。氯是一种主要的化学品
英文摘要
Exposure to chlorine gas (Cl2) presents a significant threat to public health. Chlorine is a leading chemical
produced by volume in the US. Exposure to Cl2 has occurred as a result of train derailments, accidental
misuse by swimming pool maintenance workers, accidents at water treatment facilities, and chemical warfare.
Intentional exposure is a major concern since Cl2 is both a chemical warfare agent and potential chemical
terror agent. Diagnostic biomarkers are needed to determine the extent of Cl2 exposure to humans and to
predict outcomes, which ultimately could lead to improved therapeutic support and countermeasures. The Ford
lab discovered that both Cl2 and HOCl target host plasmalogen lipids, resulting in 2-chlorofatty aldehyde (2-CLFALD) and 2-chlorofatty acid (2-CLFA) production. These chlorinated lipids accumulate to robust levels in
lung and plasma of mice exposed to sub-lethal amounts of chlorine gas. In recent unpublished studies we have
shown plasma 2-CLFA levels are elevated 40-fold in a five-subject cohort of humans exposed to chlorine at a
water treatment facility near Birmingham, Alabama. Taken together, we have shown chlorinated lipids derived
from plasmalogen oxidation are currently the best biomarkers of Cl2 exposure to humans and have the
potential to be used to predict future outcomes that could lead to improved care following exposure.!Plasma
chlorinated lipids are quantified using LC/MS detection employing a triple quadrupole instrument. The
dependence on LC/MS detection is a limitation in implementing field analyses of Cl2 exposure using these
biomarkers. The proposed studies will address this problem by identifying chlorolipid-modified proteins
produced following Cl2 exposure. Future studies producing antibodies to chlorolipid-modified proteins could
then be used to develop diagnostic kits. It is proposed that chlorinated lipids covalently modify proteins.
The identification of specific proteins and amino acid residues modified by chlorinated lipids will be used in
future studies to develop antibodies that can be used for rapid detection assays. Additionally, it is envisioned
that identifying chlorinated lipid-modified proteins as a result of Cl2 exposure may provide new targets for future
investigations to develop countermeasures to Cl2 exposure. There are three specific aims.
Specific Aim 1 will identify amino acid motifs and proteins modified by 2-CLFALD.
Specific Aim 2 will identify amino acid motifs and proteins modified by 2-CLFA.
Specific Aim 3 will identify chlorinated lipid-modified proteins in lung and plasma from mice exposed to Cl2.
These studies will identify chlorinated lipid-modified proteins, and show that they are present in plasma of Cl2
exposed mice. Furthermore, these proposed R21 studies have the potential to lead to new investigations in the
future to develop improved countermeasures for, and improve outcomes of, Cl2 exposure.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Halolipid-Neutrophil Extracellular Trap Axis in Halogen Lung Injury
-
批准号:10685387
-
项目类别:
-
资助金额:$45.0万
-
财政年份:2022
-
负责人:DAVID A. FORD
-
依托单位:
Halolipid-Neutrophil Extracellular Trap Axis in Halogen Lung Injury
-
批准号:10507044
-
项目类别:
-
资助金额:$46.29万
-
财政年份:2022
-
负责人:DAVID A. FORD
-
依托单位:
Neutrophil-dependent mediators of sepsis
-
批准号:9578653
-
项目类别:
-
资助金额:$29.53万
-
财政年份:2018
-
负责人:DAVID A. FORD
-
依托单位:
Chlorinated lipids in sepsis
-
批准号:9132272
-
项目类别:
-
资助金额:$45.99万
-
财政年份:2015
-
负责人:DAVID A. FORD
-
依托单位:
Chlorinated lipids in sepsis
-
批准号:8944723
-
项目类别:
-
资助金额:$47.24万
-
财政年份:2015
-
负责人:DAVID A. FORD
-
依托单位:
Chlorinated lipids in sepsis
-
批准号:10378863
-
项目类别:
-
资助金额:$5.94万
-
财政年份:2015
-
负责人:DAVID A. FORD
-
依托单位:
Chlorinated lipids in sepsis
-
批准号:10210265
-
项目类别:
-
资助金额:$32.12万
-
财政年份:2015
-
负责人:DAVID A. FORD
-
依托单位:
Chlorinated Lipids in Myocardial Ischemia/Reperfusion
-
批准号:8227162
-
项目类别:
-
资助金额:$22.5万
-
财政年份:2012
-
负责人:DAVID A. FORD
-
依托单位:
Chlorinated Lipids in Myocardial Ischemia/Reperfusion
-
批准号:8403793
-
项目类别:
-
资助金额:$17.85万
-
财政年份:2012
-
负责人:DAVID A. FORD
-
依托单位:
Serum chlorinated lipids as predictors of cardiovascular risk in lupus
-
批准号:7897511
-
项目类别:
-
资助金额:$22.95万
-
财政年份:2010
-
负责人:DAVID A. FORD
-
依托单位:
Serum chlorinated lipids as predictors of cardiovascular risk in lupus
-
批准号:8064785
-
项目类别:
-
资助金额:$18.91万
-
财政年份:2010
-
负责人:DAVID A. FORD
-
依托单位:
Novel MPO-derived plasma lipids as predictors of major adverse coronary events
-
批准号:7597135
-
项目类别:
-
资助金额:$18.38万
-
财政年份:2008
-
负责人:DAVID A. FORD
-
依托单位:
Novel MPO-derived plasma lipids as predictors of major adverse coronary events
-
批准号:7471172
-
项目类别:
-
资助金额:$22.05万
-
财政年份:2008
-
负责人:DAVID A. FORD
-
依托单位:
TSQ QUANTUM ESI-MS SURVEYOR BUNDLE: C.NEOFORMS, FUNGAL PATHOLOGY
-
批准号:6973461
-
项目类别:
-
资助金额:$6.78万
-
财政年份:2004
-
负责人:DAVID A. FORD
-
依托单位:
Plasmalogen-derived bioactive lipids in atherosclerosis
-
批准号:7258437
-
项目类别:
-
资助金额:$31.36万
-
财政年份:2004
-
负责人:DAVID A. FORD
-
依托单位:
Plasmalogen-derived bioactive lipids in atherosclerosis
-
批准号:6874978
-
项目类别:
-
资助金额:$33.08万
-
财政年份:2004
-
负责人:DAVID A. FORD
-
依托单位:
Plasmalogen-derived bioactive lipids in atherosclerosis
-
批准号:8213507
-
项目类别:
-
资助金额:$37.5万
-
财政年份:2004
-
负责人:DAVID A. FORD
-
依托单位:
TSQ QUANTUM ESI-MS SURVEYOR BUNDLE: DRUG ABUSE
-
批准号:6973460
-
项目类别:
-
资助金额:$6.78万
-
财政年份:2004
-
负责人:DAVID A. FORD
-
依托单位:
TSQ QUANTUM ESI-MS SURVEYOR BUNDLE: DIABETES
-
批准号:6973458
-
项目类别:
-
资助金额:$6.78万
-
财政年份:2004
-
负责人:DAVID A. FORD
-
依托单位:
Plasmalogen-derived bioactive lipids in atherosclerosis
-
批准号:8042324
-
项目类别:
-
资助金额:$37.5万
-
财政年份:2004
-
负责人:DAVID A. FORD
-
依托单位:
国内基金
海外基金
登录
查看更多内容
具有抗癌活性的天然产物金霉酸(Aureolic acids)全合成与选择性构建2-脱氧糖苷键
-
批准号:22007039
-
项目类别:青年科学基金项目
-
资助金额:24.0万元
-
批准年份:2020
-
负责人:王黎明
-
依托单位:
海洋放线菌来源聚酮类化合物Pteridic acids生物合成机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2019
-
负责人:朱义广
-
依托单位:
手性Lewis Acids催化的分子内串联1,5-氢迁移/环合反应及其在构建结构多样性手性含氮杂环化合物中的应用
-
批准号:21372217
-
项目类别:面上项目
-
资助金额:80.0万元
-
批准年份:2013
-
负责人:袁伟成
-
依托单位:
对空气稳定的新型的有机金属Lewis Acids催化剂制备、表征与应用研究
-
批准号:21172061
-
项目类别:面上项目
-
资助金额:30.0万元
-
批准年份:2011
-
负责人:许新华
-
依托单位:
钛及含钛Lewis acids促臭氧/过氧化氢体系氧化性能的广普性、高效性及其机制
-
批准号:21176225
-
项目类别:面上项目
-
资助金额:60.0万元
-
批准年份:2011
-
负责人:童少平
-
依托单位:
基于Zip Nucleic Acids引物对高度降解和低拷贝DNA检材的STR分型研究
-
批准号:81072511
-
项目类别:面上项目
-
资助金额:31.0万元
-
批准年份:2010
-
负责人:严江伟
-
依托单位:
海洋天然产物Makaluvic acids 的全合成及其对南海鱼虱存活的影响
-
批准号:30660215
-
项目类别:地区科学基金项目
-
资助金额:21.0万元
-
批准年份:2006
-
负责人:王世范
-
依托单位: